Table III.
Factors associated with bilateral detection in the entire cohort.
| Factors associated with bilateral detection in the entire cohort | No/Unilateral Mapping (N=162), (range, %) |
Bilateral Mapping (N=387), (range, %) | p-value | |
|---|---|---|---|---|
| Patient/Tumour-related variables | ||||
| Age (years) | 66 (40-88) | 61 (25-87) | <0.001 | |
| BMI (kg/m2) | 30 (18-55) | 29 (17-64) | 0.222 | |
| Obesity (BMI>30kg/m2) | 0.157 | |||
| No | 83 (51.2) | 225 (58.1) | ||
| Yes | 79 (48.8) | 162 (41.9) | ||
| Prior pelvic surgery | 0.496 | |||
| No | 99 (61.1) | 248 (64.4) | ||
| Yes | 63 (38.9) | 137 (35.6) | ||
| Previous vaginal delivery | 0.702 | |||
| No | 67 (41.4) | 152 (39.3) | ||
| Yes | 95 (58.6) | 235 (60.7) | ||
| Number of vaginal deliveries | 1.5 (0-6) | 1 (0-7) | 0.877 | |
| Caesarean Section | 0.123 | |||
| No | 124 (76.5) | 319 (82.4) | ||
| Yes | 38 (23.5) | 69 (17.5) | ||
| Number of caesarean section | 0 (0-3) | 0 (0-4) | 0.078 | |
| Histology | 0.076 | |||
| Endometrioid | 128 (79.0) | 331 (85.5) | ||
| Non-endometrioid | 34 (21.0) | 56 (14.5) | ||
| Grade* | 0.579 | |||
| 1 | 16 (10.3) | 43 (11.4) | ||
| 2 | 100 (64.1) | 252 (67.0) | ||
| 3 | 40 (25.6) | 81 (21.5) | ||
| Unknown | ||||
| LVSI** | ||||
| Negative | 103 (68.2) | 262 (71.4) | ||
| Positive | 48 (31.8) | 105 (28.6) | ||
| Maximum tumour diameter (mm) | 30 (1-100) | 32 (1.5-110) | 0.675 | |
| Cervical stroma invasion | 0.071 | |||
| No | 138 (85.2) | 351 (90.7) | ||
| Yes | 24 (14.8) | 36 (9.3) | ||
| Tumour diameter | 0.967 | |||
| < 20mm | 35 (21.6) | 83 (21.4) | ||
| ≥ 20mm | 127 (78.4) | 304 (78.6) | ||
| FIGO Stage | 0.071 | |||
| I-II | 139 (85.8) | 331 (85.5) | ||
| III-IV | 23 (14.2) | 56 (14.5) | ||
| Lymph node metastasis | ||||
| No | 142 (87.7) | 340 (87.8) | 0.948 | |
| Yes | 20 (12.3) | 47 (12.1) | ||
| Adjuvant treatment | ||||
| No | 70 (43.2) | (170 (43.9) | 0.925 | |
| Yes | 92 (56.8) | 217 (56.1) | ||
| Surgery-related variables | ||||
| Period of surgery | 0.028 | |||
| Learning period (01.2015/06.2017) | 21 (13.0) | 26 (6.7) | ||
| Experienced period (06.2017/12.2019) | 141 (87.0) | 361 (93.3) | ||
| Approach | 0.513 | |||
| Laparoscopy | 88 (54.3) | 198 (51.2) | ||
| Robot | 74 (45.7) | 189 (48.8) | ||
| Intra-operative complications (CTCAE) | 0.676 | |||
| No | 161 (99.4) | 382 (98.7) | ||
| Yes | 1 (0.6) | 5 (1.3) | ||
| Post-operative complications (Clavien-Dindo) | 0.012 | |||
| No | 152 (93.8) | 380 (98.2) | ||
| Yes | 10 (6.2) | 7 (1.8) | ||
| Post-operative complications | 0.682 | |||
| Grade 1-2 | 8 (80.0) | 5 (71.4) | ||
| Grade 3-5 | 2 (20.0) | 2 (28.6) | ||
| Site of mapping*** | 0.352 | |||
| Pelvic | 102 (100.0) | 381 (98.4) | ||
| Para-aortic | 0 (0.0) | 6 (1.6) | ||
| SLN metastasis | 0.022 | |||
| No | 153 (94.4) | 337 (87.1) | ||
| ITC | 1 (0.6) | 11 (2.8) | ||
| Micro | 3 (1.9) | 29 (7.5) | ||
| Macro | 5 (3.1) | 10 (2.6) | ||
* 17 unknown; ** 31 unknown; *** data on 489 cases (no mapping excluded)
BMI: body mass index; LVSI: lymph-vascular space involvement; FIGO: International Federation of Gynecology and Obstetrics; SLN: sentinel lymph node; CTCAE: Common Terminology Criteria for Adverse Events.